Glonghui, April 17, 丨 Gloria Ying (06821.HK) announced that Gloria Pharmaceutical Group (Tianjin) Co., Ltd. (hereinafter referred to as the “Company”) disclosed the full text and summary of the 2023 Annual Report on March 29, 2024. In order to allow investors to further understand the company's business situation in 2023, the company is scheduled to hold the 2023 Annual Results Briefing (hereinafter referred to as the “Annual Results Briefing”) on April 22, 2024 (Monday) from 15:00-16:00 on Panorama Network. The annual results briefing will be held remotely via the Internet. The company will respond to investors' questions via live text broadcast. Investors can log on to Panorama Network's “Investor Relations Interactive Platform” (to participate in this annual results briefing.
Attending the briefing session were: HAOHONG, Chairman and CEO of the company; Zhang Da, Executive Director, Chief Operating Officer and Chief Financial Officer; Xu Xiangke, Senior Vice President and Secretary of the Board; and Sun Xuejiao, independent non-executive director (participants are subject to actual attendance).